Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc (EDIT)
NASDAQ:EDIT
Editas Medicine (EDIT) Stock Price & Analysis
2,913 Followers
EDIT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.33 - $14.23
Previous Close$6.81
Volume1.48M
Average Volume (3M)1.46M
Market Cap
$555.92M
Enterprise Value$161.14M
Total Cash (Recent Filing)$431.97M
Total Debt (Recent Filing)$37.19M
Price to Earnings (P/E)-2.3
Beta1.83
Next Earnings
Nov 08, 2023EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding81,632,619
10 Day Avg. Volume1,379,409
30 Day Avg. Volume1,458,629
Standard Deviation0.26
R-Squared0.14
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.48
Price to Sales (P/S)192.56
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.34
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$14.80Price Target Upside124.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Editas Medicine News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EDIT FAQ
What was Editas Medicine Inc’s price range in the past 12 months?
Editas Medicine Inc lowest stock price was $6.33 and its highest was $14.23 in the past 12 months.
What is Editas Medicine Inc’s market cap?
Currently, no data Available
When is Editas Medicine Inc’s upcoming earnings report date?
Editas Medicine Inc’s upcoming earnings report date is Nov 08, 2023 which is in 20 days.
How were Editas Medicine Inc’s earnings last quarter?
Editas Medicine Inc released its earnings results on Aug 02, 2023. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.767 by $0.207.
Is Editas Medicine Inc overvalued?
According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued.
Does Editas Medicine Inc pay dividends?
Editas Medicine Inc does not currently pay dividends.
What is Editas Medicine Inc’s EPS estimate?
Editas Medicine Inc’s EPS estimate is -$0.58.
How many shares outstanding does Editas Medicine Inc have?
Editas Medicine Inc has 81,632,620 shares outstanding.
What happened to Editas Medicine Inc’s price movement after its last earnings report?
Editas Medicine Inc reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.767. Following the earnings report the stock price went up 5.665%.
Which hedge fund is a major shareholder of Editas Medicine Inc?
Among the largest hedge funds holding Editas Medicine Inc’s share is Woodline Partners LP. It holds Editas Medicine Inc’s shares valued at 23M.
---
Editas Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.80 (124.24% Upside)
$14.80 (124.24% Upside)
Blogger Sentiment
Bullish
EDIT Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 70.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.96%
12-Months-Change
Fundamentals
Return on Equity
-47.56%
Trailing 12-Months
Asset Growth
-6.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Editas Medicine Inc
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding EDIT
Vanguard Total Stock Market ETF
$19.44M
Vanguard Health Care ETF
$2.21M
iShares U.S. Tech Breakthrough Multisector ETF
$116.49K
FlexShares Morningstar US Market Factor Tilt Index Fund
$83.18K
Vanguard Russell 3000 ETF
$44.23K
Up to five ETFs with an Outperform Smart Score that hold EDIT. The ETFs are listed according to market value of EDIT within the ETF
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Vertex Pharmaceuticals
―
Sangamo Biosciences
―
---